Pershing Square Ventures: Ackman's New Evergreen Fund Has a Liquidity Problem

TL;DR: Bill Ackman's Pershing Square disclosed to shareholders around August 13, 2026 that it is launching Pershing Square Ventures Ltd., a new evergreen fund targeting pre-IPO AI and biotech companies. The vehicle can hold stakes indefinitely, including well past a portfolio company's IPO. It follows Pershing Square's April 2026 dual IPO, which raised $5 billion for the management company, $2.8 billion of it from a private placement. Evergreen sounds patient. For you as an LP, it also means no forced exit date and NAV marks you cannot independently check. I walk through what that trade actually costs.

Bill Ackman has spent two decades building a reputation on concentrated public bets and loud proxy fights. Now he wants a piece of the pre-IPO market too, and he is using his newly public balance sheet to get there. Pershing Square Inc.'s second-quarter 2026 letter to shareholders, dated August 12, confirmed the firm has "begun the process to launch a new permanent capital vehicle, Pershing Square Ventures, Ltd." The letter is blunt about the structure: PSV will be an evergreen permanent capital vehicle that lets it own companies after they go public, and it will charge less than most private venture and growth funds. Ackman has framed the pitch around access. He pointed to SpaceX's roughly $1.5 trillion valuation as proof that ordinary investors show up only after most of the growth already happened.

What Was Announced and How It's Built

The mechanics, as far as Pershing Square has disclosed them: PSV will seed its initial portfolio with private investments already sitting on Pershing Square's balance sheet, plus select positions Ackman made through his family office, according to reporting on the firm's second-quarter shareholder letter. Chief Investment Officer Ryan Israel and Ackman have described a target range running from companies worth several hundred million dollars up to decacorns above $10 billion, spanning artificial intelligence and biotechnology specifically, per a Bloomberg-sourced report carried by Hedgeweek. Pershing Square says it plans to seek SEC approval, with a launch targeted for autumn or by year-end 2026. Ackman has also said the fund will start small and is not expected to move the needle on total firm AUM at launch.

None of this happens in a vacuum. It happens four months after Pershing Square pulled off the IPO Ackman had chased since at least 2024. On April 29, 2026, Pershing Square USA (ticker PSUS) and Pershing Square Inc. (ticker PS) began trading on the NYSE in a combined offering. Simpson Thacher, counsel on the deal, confirmed gross proceeds of $5 billion, inclusive of $2.974 billion in private placement commitments settled concurrently with the IPO close, close to the $2.8 billion figure Pershing Square had disclosed earlier in its SEC registration materials and that Bloomberg reported the same week. The private placement investor base, according to Pershing Square's SEC prospectus filing, broke down as roughly 30% family offices, 25% pension funds, 22% insurance companies, 12% ultra-high-net-worth individuals, and 11% other institutional buyers. That capital is what now sits on Pershing Square's balance sheet and gives it the firepower to seed a venture arm without going hat in hand to outside LPs first.

Pershing Square's Q2 2026 results, filed with the SEC on August 12, show why the timing makes sense for the firm even if PSV stays small. The company's earnings exhibit reported fee-related earnings of $56.1 million for the quarter, up about 24% year over year, with an 82.4% FRE margin. PSUS alone contributed two-thirds of a quarter's worth of management fees at 2.0% annually, a fee stream the firm's core funds don't carry at that rate. A new permanent-capital vehicle is, from Pershing Square's side of the table, another annuity. From an LP's side, it's a different question entirely.

Why the Evergreen Label Is Doing a Lot of Work Here

Here's my problem with how this gets described in the press. Evergreen is being sold as a feature: patient capital, no fire sales, no artificial deadline forcing a fund to dump a good company just because year ten arrived. That part is true and it is genuinely better for the underlying businesses. Founders don't want an investor who has to exit by a specific date regardless of market conditions.

But you are not the founder. You are the LP, or in PSV's likely retail-facing wrapper, the shareholder. And for you, "no forced exit" cuts both ways. A traditional closed-end drawdown fund has a stated term, typically 10 to 12 years with extensions, and a contractual obligation to return capital. You know, roughly, when you get your money and profit back. An evergreen fund has no such date. Pershing Square can hold a stake in a biotech company for 3 years or 13 years. That's the whole design. The fund's managers decide when a position gets marked, sized up, or sold, and there is no calendar forcing their hand.

Now combine that with NAV marks on illiquid pre-IPO stakes. Public securities get a price every day from an exchange. A private AI startup does not. Its "value" on PSV's books between funding rounds is an estimate, usually based on comparable company multiples, the last funding round price, or a discounted cash flow model that a handful of people inside the fund construct. Research on evergreen structures across private equity, credit, and infrastructure notes these vehicles typically hold only 10% to 20% of assets in anything liquid, with the rest priced periodically rather than continuously. When a fund can hold a position indefinitely and prices it internally, the incentive to mark generously, especially ahead of a subscription period when new money is buying in at that NAV, is structural. It's not a matter of anyone acting in bad faith.

Ackman's version of this has one feature that softens the risk and one that does not. It's softened because Pershing Square is now a public company itself. PS and PSUS trade every day, the SEC requires quarterly filings, and Ackman has a public reputation and a stock price riding on how PSV performs and how honestly it gets reported. That accountability layer does not exist for a typical evergreen retail feeder fund run by a manager nobody has heard of, where the only public signal is the NAV the sponsor itself publishes. This is a real, meaningful difference, and it is the strongest argument in Pershing Square's favor.

It is not, however, a substitute for a redemption mechanism. A public stock price for PS or PSUS tells you nothing about whether you, as a PSV holder, can get your capital out of the vehicle on a given day, at what price, or whether that price reflects an independent valuation of the underlying pre-IPO stakes. Those questions sit inside PSV's own governing documents, and as of this writing, Pershing Square has not published the redemption terms, valuation policy, or gating provisions publicly. Ackman himself has said the fund starts small and is not expected to be material to firm AUM. That also means it can absorb losses or lock-ups quietly, without moving a needle anyone outside the fund is watching.

What to Actually Check Before Putting Money Into Any Evergreen Pre-IPO Vehicle

Whether it's PSV or one of the roughly $400 billion in evergreen product launches PitchBook has tracked across private equity, credit, and infrastructure since 2019, the due diligence checklist is the same. Most retail-facing "access" marketing skips straight past these questions.

What to check	Why it matters	Red flag
Redemption terms	Determines whether "evergreen" means quarterly liquidity or effectively none	Redemptions "subject to fund discretion" with no stated cap or frequency
Gating provisions	Funds can cap redemptions at 5% or less of NAV per quarter when many holders want out at once	No disclosed gate percentage, or a gate that's been triggered before at a sister fund
NAV methodology	Illiquid stakes are priced by estimate, not by a market, so the model matters	Marks set solely by the manager with no outside check
Independent valuation	A third-party valuation firm reduces (does not eliminate) the incentive to mark generously	"Internal valuation committee" is the only party mentioned
Lockup period	Minimum holding time before any redemption request can even be submitted	Lockup longer than 2 years with no early-exit provision at any price
Sponsor co-investment	Whether the manager's own capital sits alongside yours, and on what terms	Sponsor capital gets preferential redemption rights over LP capital
Fee structure	Management fee on NAV plus performance fee changes your break-even math	Performance fee calculated on unrealized, unaudited marks rather than realized gains

On the specific points Pershing Square has addressed: fees are expected to run "substantially lower" than typical private venture and growth funds, according to the firm's own communications, though it has not published an exact number for PSV. On every other line in that table, the public record so far is silent. That's not necessarily a black mark this early. The SEC approval process Pershing Square says it's pursuing will force a good deal of that disclosure into the open before anyone can actually invest. But it means anyone excited about this fund today is reacting to a shareholder letter, not a prospectus.

Where This Could Go Wrong

Early-stage AI and biotech companies fail for reasons that have nothing to do with fund structure. They burn cash faster than a growth model assumes. Biotech names get rejected by the FDA or fail a Phase 3 trial. AI companies with venture-scale valuations sometimes turn out to be renting the same GPU capacity and customer list as five competitors, and one of them doesn't survive the shakeout. An evergreen structure removes timing pressure from Pershing Square's side, not stock-picking risk. If Ackman backs the wrong decacorn, holding it forever doesn't fix that; it just means the mark-down shows up on paper for years before anyone is forced to admit it in cash terms.

There's also a concentration risk specific to this launch. The initial portfolio is seeded from Pershing Square's own balance sheet and Ackman's family office holdings. That means PSV's first NAV print isn't independently discovered through arm's-length third-party capital deployment. It's a transfer of positions the firm already owns, priced by the firm doing the transferring. I'd want to see exactly how those transfer prices were set and by whom before assuming day-one NAV is clean.

Finally, remember that Pershing Square itself is not immune to public-market stress. PS and PSUS shares can fall regardless of what's happening inside PSV, and a period of underperformance or bad press for Ackman personally, and he's no stranger to that, could affect subscription demand for PSV even if the underlying pre-IPO portfolio is fine. Evergreen capital protects portfolio companies from forced sales. It does not protect the sponsor's reputation, and reputation is a real input into whether new capital keeps flowing in to fund those "grow with progress" plans Ackman described.

For more on this, see our coverage of AlpInvest's $1.7 Billion Continuation Vehicle Fund: What a 393% Jump Signals, LP-Led Secondaries and the NAV Discount: Why Fund Stakes Trade Below Reported Value, How to Vet a GP-Led Continuation Fund Before You Commit Capital, and Side Pockets in Hedge Funds: How a Legitimate Tool Can Trap Your Capital for Years.

Frequently Asked Questions

What is Pershing Square Ventures Ltd.?

Pershing Square Ventures Ltd. is a new evergreen, permanent-capital fund from Bill Ackman's Pershing Square, disclosed to shareholders around August 13, 2026, that will invest in pre-IPO companies focused on artificial intelligence and biotechnology and can continue holding those stakes after the companies go public.

How is an evergreen fund different from a traditional venture fund?

A traditional closed-end venture fund has a fixed term, typically 10 to 12 years, and must eventually return capital to investors. An evergreen fund has no set end date, allows the manager to hold or sell positions indefinitely, and often permits periodic subscriptions and redemptions at net asset value rather than one fixed capital call and one fixed wind-down.

Why does Pershing Square's public listing matter for this fund's risk profile?

Because Pershing Square Inc. and Pershing Square USA trade publicly on the NYSE and file quarterly SEC reports, there is an outside accountability layer that most evergreen retail vehicles from lesser-known sponsors don't have. That reduces, but does not eliminate, the valuation and disclosure risks inherent to any fund holding illiquid, internally priced pre-IPO stakes.

What should an accredited investor check before investing in a similar evergreen pre-IPO vehicle?

Check the redemption terms and any gating provisions that could cap withdrawals during stress, the NAV methodology and whether an independent third party reviews the marks, the lockup period, the fee structure, and whether the sponsor's own capital is co-invested on the same redemption terms as outside investors.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.